{"created":"2023-10-02T02:44:34.795700+00:00","id":2000052,"links":{},"metadata":{"_buckets":{"deposit":"1e8a2e02-25f5-476d-98de-d0a17e1b0e6a"},"_deposit":{"created_by":11,"id":"2000052","owner":"11","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"2000052"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:02000052","sets":["13:40"]},"author_link":["4137"],"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2023-09-20"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The immune response to cancer serves an important role in disease progression and patient prognosis. For triple‑negative breast cancer showing aggressive behavior, immunotherapy has a good efficacy because of the potent immunogenicity of this type of cancer. However, the dominant subtype, luminal human epidermal growth factor receptor‑2 (HER2)‑negative breast cancer, is less immunogenic. To determine whether luminal HER2‑negative cancer reacts to the anticancer immune response, the present study analyzed the status and prognostic value of the principal immunological biomarkers of breast cancer, including tumor‑infiltrating lymphocytes (TILs), CD8+ T lymphocytes, the major histocompatibility complex and programmed cell death ligand‑1 (PD‑L1). The biomarkers were compared between patients with luminal HER2‑negative breast cancer and those with immunogenic subtypes including triple‑negative and HER2‑overexpressed breast cancer. A total of 71 patients with primary breast cancer were classified into the immunogenic non‑luminal (n=23) and less immunogenic luminal HER2‑negative groups (n=48) based on immunogenicity. In the luminal HER2‑negative group, compared with patients with low TIL levels, those with high TIL levels were at an advanced stage of cancer (P=0.024) and showed worse relapse‑free survival (P=0.057); however, the remaining biomarkers exhibited no association with cancer progression or prognosis. In the non‑luminal group, patients with high TIL levels showed significantly better RFS than those with low TIL levels (P=0.014). Compared with non‑luminal patients negative for PD‑L1, those positive for PD‑L1 exhibited better overall survival (P=0.064). Notably, TIL status was found to exhibit contrasting prognostic predictions based on immunogenicity. In conclusion, TILs are a strong candidate for prognostic prediction in breast cancer, regardless of the subtype. PD‑L1 is a potential candidate for prognostic prediction in immunogenic breast cancers, but not in the luminal HER2‑negative subtype.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第301号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3892/ol.2023.13750","subitem_relation_type_select":"DOI"}},{"subitem_relation_type":"hasVersion","subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10028224/","subitem_relation_type_select":"URI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"36960188","subitem_relation_type_select":"PMID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright: © Murazawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.","subitem_rights_language":"en"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1689051968263":{"attribute_name":"助成情報","attribute_value_mlt":[{"subitem_award_numbers":{"subitem_award_number":"10671249","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10671249/"},"subitem_award_titles":[{"subitem_award_title":"肺癌に対するMAGE蛋白標的免疫治療の試みと細胞傷害因子遺伝子導入併用効果の検討","subitem_award_title_language":"ja"},{"subitem_award_title":"DEVELOPMENT OF IMMUNOTHERAPY TARGETING MAGNEPROTEIN FOR LUNG CANCER","subitem_award_title_language":"en"}],"subitem_funder_identifiers":{"subitem_funder_identifier":"https://doi.org/10.13039/501100001691","subitem_funder_identifier_type":"Crossref Funder"},"subitem_funder_names":[{"subitem_funder_name":"日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]},{"subitem_award_numbers":{"subitem_award_number":"13671380","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671380/"},"subitem_award_titles":[{"subitem_award_title":"腫瘍抗原MUC1ムチンを標的にした樹状細胞ワクチン癌免疫療法の開発とその臨床応用","subitem_award_title_language":"ja"},{"subitem_award_title":"Development of Dendritic Cell Vaccine Immunotherapy of Cancer Targeting MUC1 Mucin and Its Clinical Application","subitem_award_title_language":"en"}],"subitem_funder_identifiers":{"subitem_funder_identifier":"https://doi.org/10.13039/501100001691","subitem_funder_identifier_type":"Crossref Funder"},"subitem_funder_names":[{"subitem_funder_name":"日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]},{"subitem_award_numbers":{"subitem_award_number":"14571262","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-14571262/"},"subitem_award_titles":[{"subitem_award_title":"肺癌における腫瘍関連抗原90K/Mac-2 Binding Proteinの発現解析および同抗原を標的とした癌免疫療法の開発","subitem_award_title_language":"ja"},{"subitem_award_title":"Analysis of expression of tumor-associated antigen, 90 K/Mac-2 binding protein (M2BP) in lung cancer and development of cancer immunotherapy targeting M2BP","subitem_award_title_language":"en"}],"subitem_funder_identifiers":{"subitem_funder_identifier":"https://doi.org/10.13039/501100001691","subitem_funder_identifier_type":"Crossref Funder"},"subitem_funder_names":[{"subitem_funder_name":"日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]},{"subitem_award_numbers":{"subitem_award_number":"15591340","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15591340/"},"subitem_award_titles":[{"subitem_award_title":"癌抗原MUC1ムチンを標的にした樹状細胞ワクチン癌免疫療法の開発とその臨床応用","subitem_award_title_language":"ja"},{"subitem_award_title":"Establishment of dendritic cell vaccines targeting a tumor antigen, MUC1 and application for its clinical therapeutics for cancer","subitem_award_title_language":"en"}],"subitem_funder_identifiers":{"subitem_funder_identifier":"https://doi.org/10.13039/501100001691","subitem_funder_identifier_type":"Crossref Funder"},"subitem_funder_names":[{"subitem_funder_name":"日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"村澤, 千沙","creatorNameLang":"ja"},{"creatorName":"ムラザワ, チサ","creatorNameLang":"ja-Kana"},{"creatorName":"Murazawa, Chisa","creatorNameLang":"en"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-10-02"}],"filename":"Med_B301.pdf","filesize":[{"value":"1.8 MB"}],"format":"application/pdf","licensetype":"license_5","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/2000052/files/Med_B301.pdf"},"version_id":"5a668c67-2191-4772-9f28-641d8e3ae67b"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-10-02"}],"filename":"Med_B301_abstract.pdf","filesize":[{"value":"53 KB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/2000052/files/Med_B301_abstract.pdf"},"version_id":"ec6c6686-b49c-4da2-997d-d214706267d3"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-10-02"}],"filename":"Med_B301_result.pdf","filesize":[{"value":"82 KB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/2000052/files/Med_B301_result.pdf"},"version_id":"624c5f09-2aa3-42b7-a685-b24ac38fd456"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"biomarker","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"MHC","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"PD-L1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"TILs","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"CD8+ Tlymphocytes","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Status and prognostic value of immunological biomarkers of breast cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Status and prognostic value of immunological biomarkers of breast cancer","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-10-02"},"publish_date":"2023-10-02","publish_status":"0","recid":"2000052","relation_version_is_last":true,"title":["Status and prognostic value of immunological biomarkers of breast cancer"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-10-16T02:33:32.478768+00:00"}